Navigation path

Pharmaceuticals - Community Register

  

Community list of not active orphan medicinal products


WITHDRAWN  

Product information

2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate trihydrate

EU orphan designation number: EU/3/08/590
Active ingredient: 2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate trihydrate
Indication: Treatment of acute myeloid leukaemia
Sponsor: AstraZeneca AB
151 85 Södertälje, Sverige

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
09/12/2008 Orphan designation EMEA/OD/060/08 (2008)8244 of 05/12/2008
17/06/2014 Change of name and/or address of sponsor
18/06/2015 Removal of orphan designation from Community Register